Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

Antiviral therapy - 1 Jun 2003

Bongiovanni Marco, Bini Teresa, Adorni Fulvio, Meraviglia Paola, Capetti Amedeo, Tordato Federica, Cicconi Paola, Chiesa Elisabetta, Cordier Laura, Cargnel Antonietta, Landonio Simona, Rusconi Stefano, d'Arminio Monforte Antonella

Abstract excerpt

We evaluated the virological outcome of lopinavir/ritonavir (LPV/RTV) in 224 HIV-1-infected and protease inhibitor (PI)-experienced patients showing virological failure to a highly active antiretroviral therapy (HAART) regimen and followed up for at least 3 months. At baseline, the median level o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lopinavir

Share to Proportional Hazards Models

Share to Pyrimidinones

Share to Ritonavir

Share to Salvage Therapy

Share to Viremia

Source

Identifiers

PMID: 12924537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12924537-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.PMID 12924537Read ↗

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.Semantic proximity Read ↗

Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.Semantic proximity Read ↗

Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).Semantic proximity Read ↗

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.Semantic proximity Read ↗

Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.Semantic proximity Read ↗

Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?Semantic proximity Read ↗

Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.Semantic proximity Read ↗

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.Semantic proximity Read ↗

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.Semantic proximity Read ↗

Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.Semantic proximity Read ↗

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.